PureTech Health snags $100M to fund af­fil­i­ates; PolyPid takes a third stab at IPO

→ Lon­don-list­ed, Boston-based PureTech Health has bagged $100 mil­lion (£72 mil­lion) in a plac­ing to con­tin­ue fund­ing its biotech af­fil­i­ates — a fair­ly di­verse group that in­cludes weight loss treat­ment de­vel­op­er Gele­sis, an­ti-ag­ing start­up resTOR­bio and dig­i­tal ther­a­peu­tics com­pa­ny Ak­ili In­ter­ac­tive. The pro­ceeds will be di­vid­ed be­tween three types of pro­grams: more ad­vanced ones like Ak­ili’s video game for AD­HD, which is in PhI­II; as­sets mak­ing the leap from PhI to PhII/III; and pre­clin­i­cal lym­phat­ic bi­ol­o­gy-fo­cused can­di­dates look­ing to en­ter the clin­ic. “We are con­fi­dent that our en­tre­pre­neur­ial and flex­i­ble struc­ture will con­tin­ue to yield suc­cess­es in the years to come, and we are grate­ful for the tremen­dous sup­port from a broad group of ex­ist­ing as well as new in­vestors in this plac­ing,” said PureTech CEO Daphne Zo­har in a state­ment. “And most im­por­tant­ly, for shar­ing our vi­sion of build­ing a new kind of bio­phar­ma­ceu­ti­cal com­pa­ny po­si­tioned to de­liv­er nov­el cat­e­gories of med­i­cine to pa­tients.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.